Notice to our subscribers currently receiving printed copies of our magazine: Due to COVID-19, we are delivering each issue to you via email. Please note your issues will also still be delivered to you via postal mail, and will be awaiting your return to the office. If you wish to change your delivery address, or delivery preference, you can do so via our online subscription form.
Second Genome will use its Microbiome Analytics Platform throughout the collaboration to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. / read more /
The medical service volunteer programs will allow their employees who are licensed medical professionals to help fight against COVID-19 while maintaining their base pay. / read more /
Belgian biopharmaceutical company, UCB, has successfully completed its acquisition of Ra Pharmaceuticals, which is now a wholly-owned subsidiary of the company. / read more /
EMA's CHMP has recommended the use of remdesivir, an investigational antiviral medicine, in compassionate use programs across the European Union. / read more /
The companies will collaborate on research and development solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. / read more /
Suppliers to the bio/pharma industry are sharing news about the business operations during the global COVID-19 pandemic. To view current information about the company’s business operations, click the company name. / read more /
Horizon Discovery has announced that it has expanded its cell-based clustered regularly interspaced short palindromic repeats (CRISPR) screening services to include primary human B cells, which complements the T cell screening service. / read more /
Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success. / read more /
Whether refitting existing spaces or building new, the need for quick build times, flexibility, and production efficiency is driving trends in bio/pharma facility construction. / read more /
Catalent’s Better Treatments by Design™ service offers partners access to solutions and technology to make optimal decisions throughout the development process to achieve successful new treatments that address patient needs. / read more /
Our commercial manufacturing capabilities span the requirements of Pfizer’s global small-molecule portfolio. As your CDMO, we harness those resources and look forward to collaborating with you. / read more /
Shimadzu celebrates in 2020 its 50th anniversary in mass spectrometry. The company offers a comprehensive range of products and has significantly driven this technology in recent years. / read more /
In Pharmaceutical Technology's ongoing Pharmacopoeia Compliance Series, experts explain the revision process for global and national pharmacopoeias, best practices for monitoring changes, and how to participate in revisions. Other features include FDA warning letters, building a quality culture, and essentials for DOE and QRM.
